drugset / Trial / NCT01558271

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01558271

Phase 3 Completed 492 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.

Timeline

Start
2012-03
Primary completion
2013-10
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous
Comparator Liraglutide Peptide 0.9 mg Subcutaneous